Licensing in Genetics 12-13 September 2006 Vienna
In times when in-licensing is the preferred form of collaboration in the generic industry, learning more about the process and its specific features can provide your company with the crucial competitive advantage. See what experts in the field have to say on current issues of in-and out-licensing and exploit the possibility to learn how to search new license partners and gain independence. Discuss the future of the in-licensing business model in interactive panel discussions and networking breaks.
Listen how most advanced generic companies overcome major challenges in In- & Out-Licensing;
Explore the major non-financial aspects of a licensing deal;
Answer your questions about the trends in generic industry;
Network with decision makers from leading generic companies;
And much more…
Sigrid Dienel, Director Business Development/Project Coordination, STADA
Elmar Schäfer, CEO, BioGenerIX AG
Marta Vila, Head Pharmacist, Business Development & Portfolio Manager, Sandoz
Peter Bachmann, Licensing EU, BfaRm
Dilip Shah, Member of the Management Board, International Generic Pharmaceutical Alliance (IGPA) and Secretary General, Indian Pharmaceutical Alliance (IPA)
- Emerging trends for generic markets
- Non-financial aspects in in-licensing negotiations
- Sustainability of in-licensing from the long-term point of view
- In-licensing versus in-house production
CEOs, CSOs, VPs, Senior Executives, Head Directors, Managers of: Business Development and Licensing, commercial, licensing, technology licensing, patent licensing, product licensing & development, licensing & external research, regulatory affairs, strategic planning, corporate development.
